Related references
Note: Only part of the references are listed.Aspirin in essential thrombocythemia. For whom? What formulation? What regimen?
Marco Cattaneo
HAEMATOLOGICA (2023)
Omalizumab alleviates pruritus in myeloproliferative neoplasms
Anna Ravn Landtblom et al.
HAEMATOLOGICA (2023)
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS-911543 JAK2 inhibitor
Naseema Gangat et al.
BLOOD CANCER JOURNAL (2023)
Sodium-glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases
Naseema Gangat et al.
AMERICAN JOURNAL OF HEMATOLOGY (2023)
How do valence and meaning interact? The contribution of semantic control
Naseema Gangat et al.
AMERICAN JOURNAL OF HEMATOLOGY (2023)
International Consensus Classification for myeloid neoplasms at-a-glance
Attilio Orazi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2023)
The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms
Jurgen Thiele et al.
AMERICAN JOURNAL OF HEMATOLOGY (2023)
Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
Ayalew Tefferi et al.
HAEMATOLOGICA (2023)
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
Claire N. Harrison et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
The international consensus classification of myeloid neoplasms and acute leukemias: Myeloproliferative neoplasms(vol 98,pg 166,2023)
Juergen Thiele et al.
AMERICAN JOURNAL OF HEMATOLOGY (2023)
Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival
Naseema Gangat et al.
AMERICAN JOURNAL OF HEMATOLOGY (2023)
Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2023)
Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model
Kotaro Shide et al.
BLOOD CANCER JOURNAL (2023)
Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia
Faiqa Farrukh et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach COMMENT
Daniel A. Arber et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
John Mascarenhas et al.
BLOOD (2022)
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera
Alessandra Carobbio et al.
BLOOD CANCER JOURNAL (2022)
Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy
Emanuela Sant'Antonio et al.
BLOOD REVIEWS (2022)
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study
Francesco Passamonti et al.
LANCET HAEMATOLOGY (2022)
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates
Giuseppe G. Loscocco et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Daniel A. Arber et al.
BLOOD (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Joseph D. Khoury et al.
LEUKEMIA (2022)
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
Ruben Mesa et al.
LEUKEMIA (2022)
Momelotinib for myelofibrosis: 12-year survival data and retrospective comparison to ruxolitinib
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Perioperative management of myeloproliferative neoplasms: A pan-Canadian physician survey and international expert opinion
Natasha Szuber et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Pregnancy and childbirth outcomes in women with myeloproliferative neoplasms-a nationwide population-based study of 342 pregnancies in Sweden
Anna Ravn Landtblom et al.
LEUKEMIA (2022)
Once- versus Twice-Daily Aspirin in Patients at High Risk of Thrombotic Events: Systematic Review and Meta-Analysis
Beatrice Mainoli et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2021)
Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study
Sylvie Tondeur et al.
LEUKEMIA (2021)
Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis
Jan Philipp Bewersdorf et al.
LEUKEMIA (2021)
A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series
Caleb J. Smith et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations
Naseemap Gangat et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms
Karlo Huenerbein et al.
ANNALS OF HEMATOLOGY (2021)
JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy
Naseema Gangat et al.
BLOOD (2021)
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial
Tiziano Barbui et al.
LANCET HAEMATOLOGY (2021)
Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival
Ghaith Abu-Zeinah et al.
LEUKEMIA (2021)
Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program
Alessandro Rambaldi et al.
BLOOD CANCER JOURNAL (2021)
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
Paola Guglielmelli et al.
BLOOD CANCER JOURNAL (2021)
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
Tiziano Barbui et al.
LEUKEMIA (2021)
Management and outcomes of 27 pregnancies in women with myeloproliferative neoplasms
Joelle Lapoirie et al.
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE (2020)
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases
Emanuela Sant'Antonio et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Second cancers in MPN: Survival analysis from an international study
Monia Marchetti et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis
Alberto Alvarez-Larran et al.
ANNALS OF HEMATOLOGY (2020)
Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis
Lukas Ronner et al.
BLOOD (2020)
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera
Ayalew Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm-associated venous thromboembolism in a large tertiary centre in the UK
Natalia Curto-Garcia et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden
M. Hultcrantz et al.
JOURNAL OF INTERNAL MEDICINE (2020)
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia
Bianca Rocca et al.
BLOOD (2020)
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
Heinz Gisslinger et al.
LANCET HAEMATOLOGY (2020)
Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses
Pierre-Edouard Debureaux et al.
BLOOD ADVANCES (2020)
A multicenter real-life study on anticoagulant treatment with direct oral anticoagulants in patients withPh negative myeloproliferative neoplasms
Alessandra Serrao et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin
Bridget K. Marcellino et al.
BLOOD ADVANCES (2020)
PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients
Marina Kremyanskaya et al.
BLOOD (2020)
Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study
John Mascarenhas et al.
BLOOD (2020)
Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis
Arianna Masciulli et al.
BLOOD ADVANCES (2020)
Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis
Mads Lamm Larsen et al.
PLATELETS (2019)
3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups
Natasha Szuber et al.
MAYO CLINIC PROCEEDINGS (2019)
Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis
Alberto Ferrari et al.
HAEMATOLOGICA (2019)
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis
J. Mascarenhas et al.
LEUKEMIA (2019)
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
Abdulraheem Yacoub et al.
BLOOD (2019)
Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis
Alessandra Carobbio et al.
BLOOD ADVANCES (2019)
Leukocytosis and thrombosis in polycythemia vera: can clinical trials settle the debate?
Tiziano Barbui et al.
BLOOD ADVANCES (2019)
Mayo CALR mutation type classification guide using alpha helix propensity
Terra L. Lasho et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Pregnancy outcome and management of 25 pregnancies in women with polycythemia vera
Irene Bertozzi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms A Population-Based Cohort Study
Malin Hultcrantz et al.
ANNALS OF INTERNAL MEDICINE (2018)
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project
Barbara Mora et al.
HAEMATOLOGICA (2018)
MIPSS70+Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera
Tiziano Barbui et al.
LEUKEMIA (2018)
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
Tiziano Barbui et al.
BLOOD CANCER JOURNAL (2018)
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting
Valerio De Stefano et al.
BLOOD CANCER JOURNAL (2018)
Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data
Arianna Ghirardi et al.
BLOOD CANCER JOURNAL (2018)
Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea
Rossella Renso et al.
BLOOD CANCER JOURNAL (2018)
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project
Barbara Mora et al.
HAEMATOLOGICA (2018)
Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger
Natasha Szuber et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features
Anna L. Godfrey et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions
Florian H. Heidel et al.
LEUKEMIA (2018)
Response to Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions by Heidel et al.
Giovanni Barosi et al.
LEUKEMIA (2018)
Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera
Tiziano Barbui et al.
BLOOD CANCER JOURNAL (2018)
Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo
Emmanuelle Verger et al.
BLOOD CANCER JOURNAL (2018)
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases
Valerio De Stefano et al.
BLOOD CANCER JOURNAL (2018)
Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates
Natasha Szuber et al.
BLOOD CANCER JOURNAL (2018)
The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera
Nikolai A. Podoltsev et al.
BLOOD ADVANCES (2018)
Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance
Daniela Barraco et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo clinic experience with 84 consecutive cases
Sravanthi Lavu et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
The effect of arterial hypertension on thrombosis in low-risk polycythemia vera
Tiziano Barbui et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2017)
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
Alberto Alvarez-Larran et al.
HAEMATOLOGICA (2017)
Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea
Genevieve Douglas et al.
LEUKEMIA & LYMPHOMA (2017)
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
Alberto Alvarez-Larran et al.
HAEMATOLOGICA (2017)
Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera
Guilin Tang et al.
HAEMATOLOGICA (2017)
No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials
Tiziano Barbui et al.
HAEMATOLOGICA (2017)
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
Francesco Passamonti et al.
LANCET ONCOLOGY (2017)
Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
A. Tefferi et al.
LEUKEMIA (2017)
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
F. Passamonti et al.
LEUKEMIA (2017)
Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients
S. Cerquozzi et al.
BLOOD CANCER JOURNAL (2017)
Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations
D. Barraco et al.
BLOOD CANCER JOURNAL (2017)
Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera
Guilin Tang et al.
HAEMATOLOGICA (2017)
No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials
Tiziano Barbui et al.
HAEMATOLOGICA (2017)
Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study
Tiziano Barbui et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms
Lisa Pieri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia
Yoseph C. Elala et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group
Giada Rotunno et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors
Brianna E. Vaa et al.
ANNALS OF HEMATOLOGY (2016)
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
Srdan Verstovsek et al.
HAEMATOLOGICA (2016)
Survival after splanchnic vein thrombosis: A 20-year nationwide cohort study
Kirstine Kobberoe Sogaard et al.
THROMBOSIS RESEARCH (2016)
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
Srdan Verstovsek et al.
HAEMATOLOGICA (2016)
Targeted deep sequencing in polycythemia vera and essential thrombocythemia
Ayalew Tefferi et al.
BLOOD ADVANCES (2016)
White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study
Tiziano Barbui et al.
BLOOD (2015)
Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study
Malin Hultcrantz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Long-term Clinical Outcomes of Splanchnic Vein Thrombosis Results of an International Registry
Walter Ageno et al.
JAMA INTERNAL MEDICINE (2015)
Myeloproliferative Neoplasms A Contemporary Review
Ayalew Tefferi et al.
JAMA ONCOLOGY (2015)
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
G. Barosi et al.
LEUKEMIA (2015)
Masked polycythemia vera diagnosed according to WHO and BCSH classification
Tiziano Barbui et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea
Alberto Alvarez-Larran et al.
ANNALS OF HEMATOLOGY (2014)
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology
Tiziano Barbui et al.
BLOOD (2014)
Aquagenic pruritus in polycythemia vera: Characteristics and influence on quality of life in 441 patients
Fabian P. Siegel et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms
Koichi Takahashi et al.
BLOOD (2013)
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a
Alfonso Quintas-Cardama et al.
BLOOD (2013)
JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug
Emil T. Kuriakose et al.
HAEMATOLOGICA (2013)
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
A. Tefferi et al.
LEUKEMIA (2013)
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Brief report Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome
Tiziano Barbui et al.
BLOOD (2012)
Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera
Emil Kuriakose et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations
Francesco Passamonti et al.
BLOOD (2011)
Mouse models of myeloproliferative neoplasms: JAK of all grades
Juan Li et al.
DISEASE MODELS & MECHANISMS (2011)
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980
Jean-Jacques Kiladjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
A. Pardanani et al.
LEUKEMIA (2011)
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia
Valerio De Stefano et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
Polycythemia vera-associated acquired von Willebrand syndrome despite near-normal platelet count
Ayaew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)
Ersi Voskaridou et al.
BLOOD (2010)
Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria
Alessandra Carobbio et al.
BLOOD (2010)
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
Alberto Alvarez-Larran et al.
BLOOD (2010)
Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis
Elaine M. Boyd et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Polycythemia vera-associated pruritus and its management
Kamal S. Saini et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2010)
Acute Portal Vein Thrombosis Unrelated to Cirrhosis: A Prospective Multicenter Follow-up Study
Aurelie Plessier et al.
HEPATOLOGY (2010)
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
F. Passamonti et al.
LEUKEMIA (2010)
Leukocytosis at Diagnosis and the Risk of Subsequent Thrombosis in Patients With Low-Risk Essential Thrombocythemia and Polycythemia Vera
Naseema Gangat et al.
CANCER (2009)
JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera
Alessandra Carobbio et al.
EXPERIMENTAL HEMATOLOGY (2009)
Two rare MPL gene mutations in patients with essential thrombocythemia
Haruhiko Ohashi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
Alfonso Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia:: a retrospective survey
Marco Ruggeri et al.
BLOOD (2008)
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
Jean-Jacques Kiladjian et al.
BLOOD (2008)
MPL mutations in myeloproliferative disorders:: analysis of the PT-1 cohort
Philip A. Beer et al.
BLOOD (2008)
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
Valerio De Stefano et al.
HAEMATOLOGICA (2008)
The Role of Clopidogrel and Acetylsalicylic Acid in the Prevention of Early-Phase Graft Occlusion Due to Reactive Thrombocytosis after Coronary Artery Bypass Operation
Ilyas Kayacioglu et al.
HEART SURGERY FORUM (2008)
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment
G. Barosi et al.
LEUKEMIA (2008)
Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera
A. Pardanani et al.
LEUKEMIA (2007)
Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
A. M. Vannucchi et al.
LEUKEMIA (2007)
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
Raffaele Landolfi et al.
BLOOD (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients
N. Gangat et al.
LEUKEMIA (2007)
Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: A distinct aspirin-responsive and coumadin-resistant arterial thrombophilia
Jan Jacques Michiels et al.
PLATELETS (2006)
High molecular response rate of polycythemia vera patients treated with pegylated interferon α-2a
Jean-Jacques Kiladjian et al.
BLOOD (2006)
Long-term effects of the treatment of polycythemia vera with recombinant interferon-α
Richard T. Silver
CANCER (2006)
A phase II trial of pegylated interferon α-2b therapy for polycythemia vera and essential thrombocythemia -: Feasibility, clinical and biologic effects, and impact, on quality of life
Jan Samuelsson et al.
CANCER (2006)
Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia
Naseema Gangat et al.
CANCER (2006)
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha
AV Jones et al.
BLOOD (2006)
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
CN Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
R Marchioli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study
G Finazzi et al.
BLOOD (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
MA Elliott et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycytheinia (ECLAP)
G Finazzi
PATHOLOGIE BIOLOGIE (2004)
Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis
G Finazzi et al.
BLOOD (2003)
Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera
A Baldo et al.
BRITISH JOURNAL OF DERMATOLOGY (2002)
Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus
A Tefferi et al.
BLOOD (2002)
Pruritus in polycythaemia vera: prevalence, laboratory correlates and management
F Diehn et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Share Paper
